BB

Bret Bostwick

Person

Heard in 1 episode across 1 show since Oct 2026

Bret L. Bostwick is a physician-scientist, medical geneticist, and drug developer who serves as a venture advisor at Breyer Capital. He is known for work in genetic medicines, including oligonucleotide therapeutics, gene therapy, and gene editing.

Email alerts

Episodes

1
across 1 show

First heard

Oct 2026

Guest appearances

1

Episodes per month

Public PodLume episodes featuring it, over the last year.

Show the data
MonthEpisodes
Nov 20250
Dec 20250
Jan 20260
Feb 20260
Mar 20260
Apr 20260
May 20260
Jun 20260
Jul 20260
Aug 20260
Sep 20260
Oct 20261

Email alert

Email me when Bret Bostwick comes up on a podcast

One email a week at most, with the new episodes that mention Bret Bostwick. Free, no account needed, unsubscribe in one click.

What Bret Bostwick has said on podcasts

21 statements

  1. on Genetically validated drug targetsPositiveOct 19, 2026· Business Of Biotech

    Genetically validated targets can reduce pharmacology’s traditional failure rate.

    “it really is a way of changing what is a traditionally 90% failure rate in our field of pharmacology into a much lower rate of failure.”

    Listen at 7:37

    Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.
  2. on APOE E4 homozygosityNegativeOct 19, 2026· Business Of Biotech

    APOE E4 homozygotes have ten- to twenty-fold higher Alzheimer’s disease rates.

    “individuals that are E4. E4 homozygous have, you know, a 10 to 20 fold higher rate of Alzheimer's disease.”

    Listen at 10:05

    Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.
  3. on Genetically validated drug targetsPositiveOct 19, 2026· Business Of Biotech

    Human genetic evidence lowers clinical-trial risk for genetically validated targets.

    “these targets have less risks as we go into clinical trials because we've already learned some of what modifying that target will do based on the natural experiments that have happened in human genetics.”

    Listen at 11:05

    Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.
See all 21 statements →

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

1 episode featuring Bret Bostwick, newest first

Bret Bostwick · PodLume